melanogenesis is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
In the late 17th century, the Shroud was placed in the chapel designed for that purpose by architect Guarino Guarini and attached to both the cathedral and the Royal Palace of Turin. It remained there until 1993, when it was moved into the cathedral. Repairs were made to the Shroud in 1694 by Sebastian Valfrè, improving upon the earlier patching by the Poor Clares. Further repairs were made in 1868 by Princess Maria Clotilde of Savoy. The Shroud was first photographed in 1898, during a public exhibition. The Shroud remained the property of the House of Savoy until 1983, when it was bequeathed to the Holy See according to the terms of the will of the former king Umberto II of Italy. A fire, possibly caused by arson, threatened the Shroud on 11 April 1997. In 2002 the Holy See had the Shroud restored. The cloth backing and thirty patches were removed, making it possible to photograph and scan the reverse side of the cloth, which had been hidden from view. A faint part-image of the body was found on the back of the Shroud in 2004. The Shroud was placed back on public display (the 18th time in its history) in Turin from 10 April to 23 May 2010; and according to Church officials, more than 2 million visitors came to see it. On Holy Saturday (30 March) 2013, images of the Shroud were streamed on various websites as well as on television for the first time in 40 years.
Ginkgo prefers full sun and grows best in environments that are well-watered and well-drained. The species shows a preference for disturbed sites; in the "semiwild" stands at Tianmu Mountains, many specimens are found along stream banks, rocky slopes, and cliff edges. Accordingly, ginkgo retains a prodigious capacity for vegetative growth. It is capable of sprouting from embedded buds near the base of the trunk (lignotubers, or basal chichi) in response to disturbances, such as soil erosion. Old specimens are also capable of producing aerial roots on the undersides of large branches in response to disturbances such as crown damage; these roots can lead to successful clonal reproduction upon contacting the soil. These strategies are evidently important in the persistence of ginkgo; in a survey of the "semiwild" stands remaining in Tianmushan, 40% of the specimens surveyed were multi-stemmed, and few saplings were present.
Additionally, when physicochemical properties or structures are expressed by numbers, one can find a mathematical relationship, or quantitative structure-activity relationship, between the two. The mathematical expression, if carefully validated, can then be used to predict the modeled response of other chemical structures. A QSAR has the form of a mathematical model:
Sources: en.wikipedia.org
After the 1921 season, the East Melbourne Cricket Ground was closed and demolished to expand the Flinders Street Railyard. Having played at the East Melbourne Cricket Ground from 1882 to 1921, and having won four VFA premierships (1891–1894) and four VFL premierships (1897, 1901, 1911 and 1912) while there, Essendon was looking for a new home. It was offered grounds at the current Royal Melbourne Showgrounds, Ascot Vale; at Victoria Park, Melbourne; at Arden St, North Melbourne; and the Essendon Cricket Ground. The Essendon City Council offered the (VFL) team the Essendon Cricket Ground, announcing that it would be prepared to spend over £12,000 (equivalent to A$2,159,104 in 2022) on improvements, including a new grandstand, scoreboard and re-fencing of the oval. The club's first preference was to move to North Melbourne—a move which the North Melbourne Football Club (then in the VFA) saw as an opportunity to get into the VFL. Most of Essendon's members and players were from the North Melbourne area, and sportswriters believed that Essendon would have been taken over by or rebranded as North Melbourne within only a few years of the move. However, the VFA, desperate for its own strategic reasons not to lose its use of the North Melbourne Cricket Ground, successfully appealed to the State Government to block Essendon's move to North Melbourne. With its preferred option off the table, the club returned to Essendon, and the Essendon VFA club disbanded, with most of its players moving to North Melbourne.
Protein dimers arise from the interaction between two proteins which can interact further to form larger and more complex oligomers. For example, tubulin is formed by the dimerization of α-tubulin and β-tubulin and this dimer can then polymerize further to make microtubules. For symmetric proteins, the larger protein complex can be broken down into smaller identical protein subunits, which then dimerize to decrease the genetic code required to make the functional protein.
=== Chemical extraction === Several methods are used to separate potassium salts from sodium and magnesium compounds. The most-used method is fractional precipitation using the solubility differences of the salts. Electrostatic separation of the ground salt mixture is also used in some mines. The resulting sodium and magnesium waste is either stored underground or piled up in slag heaps. Most of the mined potassium mineral ends up as potassium chloride after processing. The mineral industry refers to potassium chloride either as potash, muriate of potash, or simply MOP. Potassium metal can be isolated by electrolysis of its hydroxide in a process that has changed little since it was first used by Humphry Davy in 1807. Although the electrolysis process was developed and used in industrial scale in the 1920s, the thermal method, reacting sodium with potassium chloride in a chemical equilibrium reaction,
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.